Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:56:02.493Z.
Calculation as of: 2026-10-06T14:56:02.493Z.
Quote observation: 2026-10-06T14:39:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c636d25f821ca328dde5756eba65a9b4f657646c0770229dc3782e5e279f5fe4
PE RATIO
N/A
Market Cap
$5.01M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.21M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio Green Med Solution, Inc. (BGMS) | $4.83M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.78M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.72M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A | 1.64 | 1.64 | 1.64 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.57M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.17M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | N/A | 79.42 | 79.42 | 79.42 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.88
Forward EPS (Est.)
$-268.80
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
